Last Updated: 2026

Akoya Biosciences

Rank#9611

Market Cap64.44M

CountryUnited States

Summary

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

History

Akoya Biosciences was founded in 2015 by Brian Frezza, CEO, and Troy Wilson, COO. The company was formed to utilize unique digital cell analysis technologies to help scientists and medical researchers better understand disease development and provide the therapeutic tools needed to fight them.

Mission

At Akoya, we believe that the exploration of data is the key to unlocking insight and furthering medical science forward. We strive to provide comprehensive and digital solutions that will enable researchers to accelerate their disease research, diagnosis and therapy development.

Vision

Our vision is to create predictive cellular models to make clinical decisions faster and more accurately. We strive to provide the best technology tools and insights to advance research and breakthrough treatments.

References

https://in.investing.com/equities/akoya-biosciences

https://www.comparably.com/companies/akoya-biosciences

https://www.crunchbase.com/organization/akoya-biosciences

https://finance.yahoo.com/quote/AKYA/

https://www.akoyabio.com

https://sec.report/CIK/0001711933

Leadership team

Mr. Brian McKelligon (Pres, CEO & Director)

Dr. Garry P. Nolan Ph.D. (Co-Founder, Independent Director & Head of the Scientific Advisory Board)

Mr. Joseph S. Driscoll (Chief Financial Officer)

Products / Services